He is appointed Project Director of the Competitiveness Cluster at Eurobiomed until 2018 (more than 80 large projects financed for more than €210 million, 9 business creations).
Today he is still a member of the Strategic Projects Council and at the same time, since 2011, Michel has been President of the investment fund “Holding Incubatrice 2” (Truffle Capital).
22 ans dans la recherche et la production de protéines recombinantes à but vaccinal : Institut Pasteur, Harvard Medical School puis dans l’industrie à Pasteur Vaccins comme Directeur du laboratoire de R&D. Co-fondateur et Directeur Scientifique de Protéine Performance SA (anticorps monoclonaux humains ; 1992-95) puis fondateur et PDG de Synt:em SA (vectorisation intracérébrale de médicaments ; 1995-2005).Ces deux entreprises visaient, sur la base du transfert de technologies, au développement de nouveaux types de médicaments, de la recherche aux premières études cliniques. Un cumul de plus de 40 M€ levés auprès des investisseurs privés, français et européens, 9 brevets et 50 publications.
He was Managing Director of CisBio IVT in 2006 (diagnostic in-vitro, Marcoule) then advisor in Biotech business creation strategy (BioTop Institut Pasteur, INSERM-Transfert Initiative, investment funds or business creators for 5 years).
At the same time, he worked for 9 years in the development of a cardiology medical device now in the pivotal clinical phase (mitral valve) as President and co-founder of Kephalios SAS (Aix -Paris; 2011-2018) which became Affluent Medical SA. Obtaining funding from 8Mio PSPC (lead partner).
CEO of the investment fund “Holding Incubatrice Biotech et Pharma” (Truffle Capital, Paris; 2011-).
Today he is also a member of the Investment Committee of the SATT AxLR accelerator.
